Reps. Brian Higgins (D–NY), Brett Guthrie (R–KY), Doris Matsui (D–CA), and Gus Bilirakis (R–FL) announced introduction of the Cancer Drug Parity Act, a bipartisan bill requiring health insurance plans that cover intravenous and injectable cancer medications to also cover orally administered cancer medications at the equivalent rate.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
